Is ANCA-Associated Vasculitis Ready for Personalized Medicine? [PDF]
Popa CA, Walsh M.
europepmc +1 more source
Infection risk associated with steroid-sparing therapies in GCA, PMR, and ANCA-associated vasculitis: A systematic review. [PDF]
Sudireddy D +6 more
europepmc +1 more source
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
D. Jayne +14 more
semanticscholar +1 more source
Rituximab therapy achieves comparable remission to cyclophosphamide in ANCA-associated vasculitis with severe kidney involvement. [PDF]
Chaudhari N +6 more
europepmc +1 more source
Exploratory Risk Assessment of Cardiovascular Diseases Using Antiphospholipid Antibody-Related Scores in Patients with ANCA-Associated Vasculitis. [PDF]
Kwon OC, Park YB, Lee SW.
europepmc +1 more source
It's not always endocarditis: splinter hemorrhages in ANCA-associated vasculitis. [PDF]
Ribitsch W, Radler A.
europepmc +1 more source
Severe Pulmonary-Renal Syndrome Due to Hydralazine-Induced ANCA-Associated Vasculitis. [PDF]
Gbenle AO +4 more
europepmc +1 more source
Mechanisms, clinical manifestations and management of cardiovascular diseases in ANCA-associated vasculitis. [PDF]
Chiara E +5 more
europepmc +1 more source

